Bristol-Myers Squibb Company (BMY) is a leading drug manufacturers-general business based in the US. It opened the day at $60.33 after a previous close of $60.2. During the day the price has varied from a low of $60.2 to a high of $61.47. The latest price was $60.72 (25 minute delay). Bristol-Myers Squibb is listed on the NYSE and employs 30,000 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Bristol-Myers Squibb's share price has had significant negative movement.
Its last market close was $60.77, which is 7.41% down on its pre-crash value of $65.63 and 32.80% up on the lowest point reached during the March crash when the shares fell as low as $45.76.
If you had bought $1,000 worth of Bristol-Myers Squibb shares at the start of February 2020, those shares would have been worth $729.87 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $955.91.
|52-week range||$44.7045 - $66.7637|
|50-day moving average||$62.2824|
|200-day moving average||$60.4415|
|Wall St. target price||$74.76|
|Dividend yield||$1.96 (3.21%)|
|Earnings per share (TTM)||$0.513|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-14)||-8.03%|
|1 month (2020-12-22)||-1.16%|
|3 months (2020-10-22)||-0.07%|
|6 months (2020-07-22)||1.45%|
|1 year (2020-01-22)||-9.95%|
|2 years (2019-01-18)||21.15%|
|3 years (2018-01-19)||-2.50%|
|5 years (2016-01-21)||-3.82%|
Valuing Bristol-Myers Squibb stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 94x. In other words, Bristol-Myers Squibb shares trade at around 94x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Bristol-Myers Squibb's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
Bristol-Myers Squibb's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.81. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Bristol-Myers Squibb's PEG ratio in relation to those of similar companies.
Bristol-Myers Squibb's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $16.8 billion (£12.3 billion).
The EBITDA is a measure of a Bristol-Myers Squibb's overall financial performance and is widely used to measure a its profitability.
To put Bristol-Myers Squibb's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$39.4 billion|
|Operating margin TTM||20.04%|
|Gross profit TTM||$18.9 billion|
|Return on assets TTM||5.39%|
|Return on equity TTM||-0.08%|
|Market capitalisation||$138.2 billion|
TTM: trailing 12 months
There are currently 15.4 million Bristol-Myers Squibb shares held short by investors – that's known as Bristol-Myers Squibb's "short interest". This figure is 4.6% down from 16.1 million last month.
There are a few different ways that this level of interest in shorting Bristol-Myers Squibb shares can be evaluated.
Bristol-Myers Squibb's "short interest ratio" (SIR) is the quantity of Bristol-Myers Squibb shares currently shorted divided by the average quantity of Bristol-Myers Squibb shares traded daily (recently around 10.0 million). Bristol-Myers Squibb's SIR currently stands at 1.54. In other words for every 100,000 Bristol-Myers Squibb shares traded daily on the market, roughly 1540 shares are currently held short.
To gain some more context, you can compare Bristol-Myers Squibb's short interest ratio against those of similar companies.
However Bristol-Myers Squibb's short interest can also be evaluated against the total number of Bristol-Myers Squibb shares, or, against the total number of tradable Bristol-Myers Squibb shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bristol-Myers Squibb's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bristol-Myers Squibb shares in existence, roughly 10 shares are currently held short) or 0.0068% of the tradable shares (for every 100,000 tradable Bristol-Myers Squibb shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bristol-Myers Squibb.
Find out more about how you can short Bristol-Myers Squibb stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb's overall score of 29.16 (as at 01/01/2019) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Bristol-Myers Squibb's total ESG risk score against those of similar companies.
Environmental score: 3.83/100
Bristol-Myers Squibb's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.82/100
Bristol-Myers Squibb's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.02/100
Bristol-Myers Squibb's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Bristol-Myers Squibb scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb has, for the most part, managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
|Total ESG score||29.16|
|Total ESG percentile||52.58|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||2|
Dividend payout ratio: 29.68% of net profits
Recently Bristol-Myers Squibb has paid out, on average, around 29.68% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.21% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb shareholders could enjoy a 3.21% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb's case, that would currently equate to about $1.96 per share.
While Bristol-Myers Squibb's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb may be investing much of the rest of its net profits in future growth.
Bristol-Myers Squibb's most recent dividend payout was on 1 February 2021. The latest dividend was paid out to all shareholders who bought their shares by 31 December 2020 (the "ex-dividend date").
Bristol-Myers Squibb's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Bristol-Myers Squibb's shares were split on a 1000000:95 basis on 7 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb shares which in turn could have impacted Bristol-Myers Squibb's share price.
Over the last 12 months, Bristol-Myers Squibb's shares have ranged in value from as little as $44.7045 up to $66.7637. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb's is 0.6467. This would suggest that Bristol-Myers Squibb's shares are less volatile than average (for this exchange).
To put Bristol-Myers Squibb's beta into context you can compare it against those of similar companies.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrödinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.